Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

For the year ended December 31, 2018, PricewaterhouseCoopers SA (“PwC”) was the Company’s auditor for the IFRS and statutory accounts. At the ordinary annual general meeting on July 6, 2018, the shareholders appointed PwC as the Company’s auditor for a term of office of one year replacing the Company’s prior auditor Ernst & Young AG (“EY”). For the year ended December 31, 2017, EY was the Company’s auditor for the IFRS and statutory accounts.

 

Audit fees for services provided by PwC in 2018 include the standard audit work performed each fiscal year necessary to allow the auditor to issue an opinion on our Financial Statements and to issue an opinion on the local statutory financial statements. Audit fees also include services that can be provided only by the external auditor such as reviews of quarterly financial results and review of our shelf registration statements and prospectus offerings.

 

Audit-related fees consisted of fees billed for assurance and related services that were reasonably related to the performance of the audit or review of our financial statements or for services that were traditionally performed by the external auditor.

 

Pre-Approval Policies and Procedures

 

In accordance with the requirements of the U.S. Sarbanes-Oxley Act of 2002 and rules issued by the SEC, we review and pre-approve of any services performed by EY and PwC. The procedure requires that all proposed future engagements of PwC for audit and permitted non-audit services are submitted to the Audit and Finance Committee for approval prior to the beginning of any such services. In accordance with this policy, all services performed by and fees paid to EY and PwC in this Item 16C, were approved by the Audit and Finance Committee.

 

ITEM 16D. Exemptions from the listing standards for audit committees

 

 Not applicable

 

ITEM 16E. Purchases of equity securities by the issuer and affiliated purchasers

 

In 2018, no purchases of our equity securities were made by or on behalf of AC Immune SA or any affiliated purchaser.

 

ITEM 16F. Change in registrant’s certifying accountant

 

Not applicable.

 

ITEM 16G. Corporate governance

 

Summary of Significant Corporate Governance Differences from Nasdaq Listing Standards

 

Our common shares are listed on the Nasdaq Global Market. We are therefore required to comply with certain of the Nasdaq’s corporate governance listing standards, or the Nasdaq Standards. As a foreign private issuer, we may follow our home country’s corporate governance practices in lieu of certain of the Nasdaq Standards. Our corporate governance practices differ in certain respects from those that U.S. companies must adopt in order to maintain a Nasdaq listing. A brief, general summary of those differences is provided as follows.

 

Independent Directors

 

Swiss law does not require that a majority of our board of directors consist of independent directors. Our board of directors therefore may include fewer independent directors than would be required if we were subject to Nasdaq Listing Rule 5605(b)(1). In addition, we are not subject to Nasdaq Listing Rule 5605(b)(2), which requires that independent directors must regularly have scheduled meetings at which only independent directors are present.

 

 138


© AC Immune 2015